• Home
  • Upcoming Virtual Events
  • Recent Virtual Events
  • LIVE! EVENT SITE
  • More
    • Home
    • Upcoming Virtual Events
    • Recent Virtual Events
    • LIVE! EVENT SITE
  • Sign In
  • Create Account

  • Orders
  • My Account
  • Signed in as:

  • filler@godaddy.com


  • Orders
  • My Account
  • Sign out

Signed in as:

filler@godaddy.com

  • Home
  • Upcoming Virtual Events
  • Recent Virtual Events
  • LIVE! EVENT SITE

Account

  • Orders
  • My Account
  • Sign out

  • Sign In
  • Orders
  • My Account

Poster Session: 11:00AM - 1:00PM ET

Patient-Derived Tumor Organoids: Characterization and Functional Applications | ATCC


PRESENTER:  

Ashley Cox | Field Application Specialist - North America


PRESENTER'S BIO: 

 Ashley Cox is a Field Application Specialist at ATCC where she provides support and technical expertise in toxicology and cell biology. She obtained her Ph.D. from the Marshall University Joan C. Edwards School of Medicine in biomedical research, with a focus on toxicology. Prior to joining ATCC, Dr. Cox’s research focused on identifying toxicological and cellular stress effects of flavoring aldehydes in vaping products using an in vitro renal model. In addition, her previous experiences as an instructor have helped shape her expertise in science education and communication. Today, she supports ATCC customers as in their research as a technical resource to help overcome experimental challenges and build robust in vitro workflows.


ABSTRACT:

The Human Cancer Models Initiative (HCMI) is a global collaboration led by the National Cancer Institute (NCI), with partners including Cancer Research UK, the Welcome Sanger Institute, Weill Cornell Medicine, Stanford University, Hubrecht Organoid Technology, and NCI-funded institutions such as the Broad Institute and Cold Spring Harbor Laboratory. The initiative develops next‑generation, patient‑derived cancer models that better capture the genomic and phenotypic complexity of human tumors compared to traditional cell lines. ATCC® is the sole distributor of the HCMI portfolio, currently providing 337 fully characterized 2-D and 3-D cancer models derived from over 28 tissue types, including colorectal, pancreatic, brain, and esophageal cancers as well as rare cancers like Wilms tumor and Ewing’s sarcoma. These models reflect diverse clinical backgrounds and retain high genomic fidelity, preserving over 80% of oncogenic drivers and maintaining transcriptional and epigenetic landscapes comparable to patient tumors. By offering clinically relevant models with available sequencing data and patient metadata through the HCMI portal, this work supports improved preclinical testing, biomarker discovery, precision oncology research, and studies of tumor heterogeneity and health disparities.

Copyright © 2026 LSE Virtual Events - All Rights Reserved.

The institution names listed are for invitation purposes only.  In no way should it imply an existing relationship between LSE and that institution.

  • Privacy Policy
  • Privacy Policy
  • Terms and Conditions

Powered by